2001, Biosimilars and Immunity

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2001

Biosimilars

Immunity

PharmaShots Weekly Snapshots (April 03 - 07, 2023)

PharmaShots

APRIL 7, 2023

TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis Date: Apr 3, 2023 | Tags: TG Therapeutics, Briumvi, Ublituximab-xiiy, Multiple Sclerosis, Regulatory, EMA, CHMP BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for (..)

Biosimilars

Biosimilars Immunity Immunization

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

Engler , a 2001 decision by the Sixth Circuit Court of Appeals. In any case, no Court can provide relief from economic harm that has already occurred because sovereign immunity bars the court from granting damages. Order at 24.

Drug Pricing

Drug Pricing Pharmaceutical Manufacturing Immunity Immunization

Pharmacist Digest

PharmaShots Weekly Snapshots (April 03 - 07, 2023)

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

Stay Connected